AOD-9604 Mechanism: A Research Overview of the hGH Fragment (2026)
A mechanism-first look at AOD-9604 — what the residue 176–191 fragment of human growth hormone is studied to do, the lipolysis-without-IGF-1 rationale, the open mechanistic questions, and how it differs from secretagogues. Research-use framing only.
AOD-9604 is one of the more conceptually elegant compounds in the metabolic-peptide space, and also one of the most misunderstood. Its appeal is a clean idea: take the part of human growth hormone responsible for mobilizing fat, leave behind the part responsible for growth, and study the first without the second. This overview is mechanism-first — what the fragment is, the lipolysis-without-IGF-1 rationale, what the research has actually shown, and what remains genuinely open. For the sourcing and supplier side, see our separate AOD-9604 research guide. Everything below is framed for laboratory research use only, with no human-outcome claims.
AOD-9604 is referenced strictly as a research chemical. This article describes its studied mechanism in preclinical models, not fat loss, body composition, or any human outcome. Nothing here is dosing or therapeutic guidance, and the compound is not approved for any human indication.
The fragment: residues 176–191 of hGH
Human growth hormone is a 191-amino-acid protein with multiple functional regions. The N-terminal portion is associated with growth-promoting activity, mediated largely through hepatic IGF-1 secretion. The C-terminal region — roughly residues 177 to 191 — has been associated in animal-model work with effects on lipid metabolism: stimulation of lipolysis and inhibition of lipogenesis in isolated adipocyte preparations.
AOD-9604 ("Anti-Obesity Drug 9604") is a synthetic peptide that replicates that C-terminal fragment, with an added N-terminal tyrosine that is not part of the native hGH sequence. The tyrosine was incorporated during synthesis to improve metabolic stability and to provide a handle for radio-iodination in early pharmacokinetic work. The result is a 17-residue peptide (16 hGH residues plus the tyrosine) — roughly 1.8 kDa, against the ~22 kDa of full hGH.
The core rationale: lipolysis without IGF-1
The whole reason AOD-9604 exists as a research tool is the separation of function. The premise, supported by preclinical observations, is that growth hormone's lipolytic activity — its studied ability to mobilize stored triglycerides into free fatty acids and glycerol in cellular models — can be engaged by this fragment without the IGF-1 stimulation, growth-plate activity, or insulin-sensitivity changes that the full hormone produces.
In the models where it has been characterized, AOD-9604 has shown lipolytic activity in adipose-tissue preparations while not producing measurable IGF-1 stimulation. That is the entire selling point: it lets investigators probe the lipid-metabolism arm of GH biology in isolation, rather than administering full recombinant hGH and then trying to disentangle the lipolytic effects from everything else the hormone does.
AOD-9604 is not a weaker growth hormone — it is a deliberately isolated arm of it. The design goal is lipolytic activity in adipocyte models with the growth-axis (IGF-1) arm left out, which is exactly what makes it a clean research tool rather than a substitute for somatropin.
What remains under investigation
Here is where careful framing matters. The lipolytic activity is a reported preclinical finding, but the exact mechanism by which the fragment produces it is not settled. The research literature has examined whether AOD-9604 acts through beta-3 adrenergic receptor pathways in adipose tissue, among other routes, but the precise receptor and downstream signaling remain an active area of investigation. A responsible reading is: the effect in models is reported; the mechanism is a working hypothesis, not a closed case.
This open question is part of what distinguishes AOD-9604 from the incretin agonists. The GLP-1 receptor and its Gs/cAMP signaling are textbook pharmacology — see the GLP-1 receptor agonist mechanism guide. AOD-9604's pathway is less resolved, which is itself useful information for anyone designing an assay around it.
How AOD-9604 differs from secretagogues
The most instructive contrast is with growth-axis secretagogues — compounds like tesamorelin, ipamorelin, and CJC-1295/ipamorelin that stimulate the body's own growth-hormone release. The two approaches point in opposite directions:
| Property | AOD-9604 | GH secretagogues |
|---|---|---|
| Acts on | Adipocyte models (mechanism under study) | GHRH / ghrelin receptors |
| Effect on endogenous GH | None — it is a fragment, not a releaser | Raises endogenous GH |
| IGF-1 | Not stimulated in models | Raised via GH release |
| Growth-axis activation | Deliberately avoided | Intended |
| Studied for | Isolated lipolytic arm | Full GH-axis effects |
A secretagogue raises the whole hormone and lets it act broadly, IGF-1 included. AOD-9604 isolates one fragment and avoids the axis. Both land under the "metabolic" umbrella, but their mechanistic logic is inverted — a point we develop in the metabolic research peptides overview.
The clinical-trial record, accurately stated
AOD-9604 was advanced through several Phase II human trials in the mid-2000s by Metabolic Pharmaceuticals (later Calzada Limited), primarily examining body-weight endpoints. The program did not advance to a Phase III registration, and the compound was de-prioritized by the sponsor. The honest summary is that a clinical record exists in trial registries but did not produce an approval. Nothing about that record supports a human-use claim for research-chemical material today; the compound is sold strictly for laboratory research.
Why mechanism understanding doesn't relax sourcing
Knowing the mechanism does not make a mislabeled vial useful. AOD-9604 is a niche, higher-cost compound with a small buyer base, which raises substitution and dilution risk — and its distinctive 17-residue length and ~1815 Da mass mean a real mass-spec confirmation actually means something. Insist on a batch-specific Certificate of Analysis with third-party HPLC purity and mass-spec identity confirmation. Start with our compound buying guides, the metabolic research goal hub, and the 2026 supplier evaluation before sourcing.
Bottom line
AOD-9604's mechanism is best understood as a deliberate isolation: the C-terminal lipolytic fragment of human growth hormone, studied for fat-mobilizing activity in adipocyte models without the IGF-1 and growth-axis effects of the full hormone. The effect is a reported preclinical finding; the exact pathway remains under investigation. It is the mechanistic opposite of a secretagogue, it carries a clinical record that stopped short of approval, and — research tool or not — it is only as useful as the vial is verified.
For research use only. This content is informational and does not constitute medical or dosing advice. All compounds referenced are for laboratory research use only — not for human consumption.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
Metabolic Research Peptides: A 2026 Overview of the Class
A research-framed map of the metabolic peptide landscape — incretin agonists, the hGH lipolytic fragment, and growth-axis secretagogues — organized by the pathway each one engages. Mechanisms only, no human-outcome claims.
Lipolysis and Fat-Metabolism Peptides in Research (2026)
A pathway-level look at how research peptides are studied to intersect lipolysis — the cAMP/HSL cascade, direct fragments vs growth-axis routes vs incretin signaling, and why 'fat metabolism' covers several distinct mechanisms. Research-use framing only.
Cagrilintide Research Overview (2026): The Amylin Analog Studied Alongside GLP-1 Peptides
A research-framed overview of cagrilintide — a long-acting amylin-receptor agonist studied in the metabolic literature, why it is mechanistically distinct from GLP-1 peptides, and how the amylin/GLP-1 co-investigation is framed in research.